Peter Salzmann Immunovant, Inc. (IMVT) insider trading activity

Peter Salzmann is Chief Executive Officer of Immunovant, Inc.. Currently has a direct ownership of 1.18 Million shares of IMVT, which is worth approximately $32.4 Million. The most recent transaction as insider was on Apr 12, 2023, when has been sold 243,832 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.18M

22.19% 3M change

11.9% 12M change

Total Value Held $32.4 Million

Peter Salzmann Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Apr 12 2023	BUY Grant, award, or other acquisition	-	243,832 Added 16.46%	1,237,764 Common Stock
Jan 11 2023	SELL Open market or private sale	$67,552 $16.8 p/Share	4,021 Reduced 0.4%	993,932 Common Stock
Oct 13 2022	SELL Open market or private sale	$25,640 $9.18 p/Share	2,793 Reduced 0.28%	997,953 Common Stock
Sep 28 2022	SELL Open market or private sale	$7,495 $4.67 p/Share	1,605 Reduced 0.16%	1,000,746 Common Stock
Aug 30 2022	SELL Open market or private sale	$9,585 $5.83 p/Share	1,644 Reduced 0.16%	1,002,351 Common Stock
Aug 17 2022	BUY Grant, award, or other acquisition	-	451,264 Added 31.01%	1,003,995 Common Stock
Jul 27 2022	SELL Open market or private sale	$6,525 $4.27 p/Share	1,528 Reduced 0.28%	552,731 Common Stock
Jun 29 2022	SELL Open market or private sale	$5,532 $4.02 p/Share	1,376 Reduced 0.25%	554,259 Common Stock
May 24 2022	SELL Open market or private sale	$5,575 $3.79 p/Share	1,471 Reduced 0.26%	555,635 Common Stock
Apr 27 2022	SELL Open market or private sale	$7,656 $4.72 p/Share	1,622 Reduced 0.29%	557,106 Common Stock
Mar 24 2022	SELL Open market or private sale	$113,439 $5.9 p/Share	19,227 Reduced 3.33%	558,728 Common Stock
Jan 07 2022	SELL Open market or private sale	$907,396 $7.25 p/Share	125,158 Reduced 17.8%	577,955 Common Stock
Aug 03 2021	BUY Grant, award, or other acquisition	-	570,613 Added 44.8%	703,113 Common Stock
Mar 19 2021	BUY Grant, award, or other acquisition	-	132,500 Added 50.0%	132,500 Common Stock

Also insider at

CRBP

Corbus Pharmaceuticals Holdings, Inc. Healthcare

Peter Salzmann

Chief Executive Officer

New York, NY

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells IMVT shares.

Notify only if

Value

Insider Trading

Get notified when an Immunovant, Inc. insider buys or sells IMVT shares.

Notify only if

Operation

Value

Type

News

Receive news related to Immunovant, Inc.

Track Activities on IMVT

Account